Stockscreener 앱 받기
0.67
13.12%
0.0777
시장 영업 전:
.67
전일 마감가:
$0.5923
열려 있는:
$0.5907
하루 거래량:
506.82K
Relative Volume:
0.15
시가총액:
$2.80M
수익:
$10.48M
순이익/손실:
$-37.74M
주가수익비율:
-0.0414
EPS:
-16.1846
순현금흐름:
$-29.03M
1주 성능:
-0.68%
1개월 성능:
-40.71%
6개월 성능:
-69.89%
1년 성능:
-96.83%
1일 변동 폭
$0.59
$0.68
1주일 범위
$0.56
$0.6831
52주 변동 폭
$0.56
$25.75
재규어 헬스 Stock (JAGX) Company Profile
명칭
Jaguar Health Inc
전화
415-371-8300
주소
200 PINE STREET SUITE 400, SAN FRANCISCO, CA
Compare JAGX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
JAGX
Jaguar Health Inc
|
0.67 | 2.47M | 10.48M | -37.74M | -29.03M | -16.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.92 | 116.41B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
785.51 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
811.45 | 50.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.76B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
353.92 | 38.40B | 4.98B | 69.60M | 525.67M | 0.5198 |
재규어 헬스 Stock (JAGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-07-07 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-07-11 | 개시 | Rodman & Renshaw | Buy |
재규어 헬스 주식(JAGX)의 최신 뉴스
Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million - South Bend Tribune
Jaguar Health Presenting January 15 at Lytham Partners Healthcare Investor Summit to Provide Updates on Near-Term Catalysts - The Marion Star
Should value investors consider Jaguar Health Inc.July 2025 Opening Moves & Weekly Breakout Watchlists - mfd.ru
Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue - hattiesburgamerican.com
Jaguar Health to Hold Investor Webcast Monday, November 17 at 8:30 AM Eastern Regarding Q3 2025 Financials & Corporate Updates - The Asheville Citizen Times
Jaguar Health Executes Debt-Reducing Equity Warrant Transactions - TipRanks
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - citizen-times.com
Jaguar Health Signs Multiple Material Agreements - TradingView
Jaguar Health (JAGX) Advances Rare Disease Program with Focus on Crofelemer - GuruFocus
Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi - Lansing State Journal
Jaguar trial cuts children’s IV support needs by up to 37% - Stock Titan
Jaguar Health Awarded $240,000 FDA Grant in Support of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs - barnstablepatriot.com
Enrollment Initiated in Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs - Pueblo Chieftain
Earnings Report: Is Jaguar Health Inc a defensive stock2025 Valuation Update & Scalable Portfolio Growth Ideas - baoquankhu1.vn
Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication - dailycommercial.com
Recent Developments in Jaguar Health - StocksToTrade
Strategic Licensing Boosts Jaguar Health’s Market Momentum - timothysykes.com
Swing Trade: Is Jaguar Health Inc on track to beat earningsJuly 2025 Drop Watch & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Jaguar Health Enters Exclusive Licensing Agreement Boosting Market Dynamics - timothysykes.com
The Surge In Jaguar Health Stock: What's Happening Now? - Sahm
Jaguar Health’s Licensing Deal Boosts Financial Prospects - StocksToTrade
Jaguar Health Soars Amid Licensing Deals and Study Breakthroughs - timothysykes.com
Jaguar Health Inc surges amid market gains - Intellectia AI
Jaguar Health IncCo & unit entered license agreement with Woodward Specialty LLCSEC filing - marketscreener.com
Jaguar Animal Health Grants U.S. Rights to Crofelemer Drugs - TipRanks
재규어 헬스 (JAGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.23%
1.25%
자본화:
|
볼륨(24시간):